The role of single-pill ACE inhibitor/ccb combination for hypertension: an Algerian view via the nominal group technique.

IF 1 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Future cardiology Pub Date : 2025-03-01 Epub Date: 2025-02-12 DOI:10.1080/14796678.2025.2465218

Brahim Kichou, Abed Bouraghda, Hadj Mohamed Ali Lahmar, Sofiane Amara, Yazid Aoudia, Yasmina Benchabi, Farid Haddoum, Adjia Kachenoura, Nadia Laredj, Leila Manamani, Mohamed Tahar Chafik Bouafia, Mohamed Chettibi

{"title":"The role of single-pill ACE inhibitor/ccb combination for hypertension: an Algerian view via the nominal group technique.","authors":"Brahim Kichou, Abed Bouraghda, Hadj Mohamed Ali Lahmar, Sofiane Amara, Yazid Aoudia, Yasmina Benchabi, Farid Haddoum, Adjia Kachenoura, Nadia Laredj, Leila Manamani, Mohamed Tahar Chafik Bouafia, Mohamed Chettibi","doi":"10.1080/14796678.2025.2465218","DOIUrl":null,"url":null,"abstract":"<p><p>Around one-third of adults in Algeria have hypertension, but > 40% are unaware they have the disease, and of those receiving treatment, only ~ 20-30% have adequate blood pressure (BP) control. Recommended starting treatment is an angiotensin converting enzyme inhibitor (ACEi) or angiotensin receptor blocker plus a calcium channel blocker (CCB) or diuretic. A single-pill combination of perindopril/amlodipine (ACEi/CCB) recently became available in Algeria. Twelve Algerian hypertension experts reviewed the clinical evidence regarding this therapeutic combination to determine its potential role for hypertension management in Algeria. The evidence indicated that this combination reduces cardiovascular outcomes and visit-to-visit BP variability, effectively controls 24-hour BP, and is well tolerated. In conclusion, the perindopril/amlodipine SPC provides a valuable new treatment option for hypertension in Algeria.</p>","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"155-166"},"PeriodicalIF":1.0000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11875506/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future cardiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/14796678.2025.2465218","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/12 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Around one-third of adults in Algeria have hypertension, but > 40% are unaware they have the disease, and of those receiving treatment, only ~ 20-30% have adequate blood pressure (BP) control. Recommended starting treatment is an angiotensin converting enzyme inhibitor (ACEi) or angiotensin receptor blocker plus a calcium channel blocker (CCB) or diuretic. A single-pill combination of perindopril/amlodipine (ACEi/CCB) recently became available in Algeria. Twelve Algerian hypertension experts reviewed the clinical evidence regarding this therapeutic combination to determine its potential role for hypertension management in Algeria. The evidence indicated that this combination reduces cardiovascular outcomes and visit-to-visit BP variability, effectively controls 24-hour BP, and is well tolerated. In conclusion, the perindopril/amlodipine SPC provides a valuable new treatment option for hypertension in Algeria.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

单片ACE抑制剂/ccb联合治疗高血压的作用：阿尔及利亚人通过名义组技术观察。

阿尔及利亚大约三分之一的成年人患有高血压，但40%的人不知道自己患有这种疾病，而在接受治疗的人中，只有20-30%的人血压得到了适当的控制。推荐开始治疗是血管紧张素转换酶抑制剂（ACEi）或血管紧张素受体阻滞剂加钙通道阻滞剂（CCB）或利尿剂。培哚普利/氨氯地平单片组合（ACEi/CCB）最近在阿尔及利亚上市。12名阿尔及利亚高血压专家审查了有关这种治疗组合的临床证据，以确定其在阿尔及利亚高血压管理中的潜在作用。有证据表明，这种组合可以降低心血管结局和每次就诊的血压变异性，有效控制24小时血压，并且耐受性良好。总之，培哚普利/氨氯地平SPC为阿尔及利亚的高血压提供了一种有价值的新治疗选择。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Future cardiology CARDIAC & CARDIOVASCULAR SYSTEMS-

CiteScore

2.80

自引率

5.90%

发文量

期刊介绍： Research advances have contributed to improved outcomes across all specialties, but the rate of advancement in cardiology has been exceptional. Concurrently, the population of patients with cardiac conditions continues to grow and greater public awareness has increased patients" expectations of new drugs and devices. Future Cardiology (ISSN 1479-6678) reflects this new era of cardiology and highlights the new molecular approach to advancing cardiovascular therapy. Coverage will also reflect the major technological advances in bioengineering in cardiology in terms of advanced and robust devices, miniaturization, imaging, system modeling and information management issues.